keyword
MENU ▼
Read by QxMD icon Read
search

Gep-net

keyword
https://www.readbyqxmd.com/read/30095460/apobec3b-high-expression-in-gastroenteropancreatic-neuroendocrine-neoplasms-and-association-with-lymph-metastasis
#1
Changyin Feng, Qiaoling Zheng, Yinghong Yang, Meifang Xu, Yuane Lian, Jianping Huang, Yiting Jiang
PURPOSE: Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3B (APOBEC3B) is known as a source of mutations in multiple cancers. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a group of heterogeneous tumors. However, the expression and significance of APOBEC3B in GEP-NENs remains unclear. MATERIALS AND METHODS: A total of 158 cases of GEP-NENs, including 78 cases of biopsy or endoscopic submucosal dissection resection specimens and 83 cases of surgical resection specimens were collected in this study...
August 8, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/30083881/a-novel-germline-mutation-at-exon-10-of-men1-gene-a-clinical-survey-and-positive-genotype-phenotype-analysis-of-a-men1-italian-family-including-monozygotic-twins
#2
REVIEW
Andrea Palermo, Ettore Capoluongo, Rossella Del Toro, Silvia Manfrini, Paolo Pozzilli, Daria Maggi, Giuseppe Defeudis, Francesco Pantano, Roberto Coppola, Francesco Maria Di Matteo, Marco Raffaelli, Paola Concolino, Alberto Falchetti
CONTEXT: Clinical phenotype variability in MEN1 syndrome exists and evidence for an established genotype-phenotype is lacking. However, a higher aggressiveness of MEN1-associated gastro-entero-pancreatic (GEP) (neuro)endocrine tumours (NETs) tumours has been reported when MEN1 gene truncating mutations are detected. We found a novel germline truncating mutation of MEN1 gene at exon 10 in a subject with an aggressive clinical behavior of GEP-NETs. Successively, other two mutant-affected familial members have been identified...
August 6, 2018: Hormones: International Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/30078166/improved-survival-with-higher-doses-of-octreotide-long-acting-release-in-gastroenteropancreatic-neuroendocrine-tumors
#3
Sally C Lau, Omar Abdel-Rahman, Winson Y Cheung
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) represent a heterogeneous group of tumors that is associated with an indolent course. Octreotide has a positive effect on disease stabilization in well-differentiated midgut NETs, but a meaningful survival analysis was not possible due to insufficient events. Higher doses of octreotide long-acting release (LAR) are often used in clinical practice for control of carcinoid symptoms and our objective was to determine if dose of octreotide correlates with survival...
August 4, 2018: Medical Oncology
https://www.readbyqxmd.com/read/30021866/evaluating-gastroenteropancreatic-neuroendocrine-tumors-through-microrna-sequencing
#4
Nicole Panarelli, Kathrin Tyryshkin, Justin Wong, Adrianna Majewski, Xiaojing Yang, Theresa Scognamiglio, Michelle Kang Kim, Kimberley Bogardus, Thomas Tuschl, Yao-Tseng Chen, Neil Renwick
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can be challenging to evaluate histologically. microRNAs (miRNAs) are small RNA molecules that often are excellent biomarkers due to their abundance, cell-type- and disease-stage specificity, and stability. To evaluate miRNAs as adjunct tissue markers for classifying and grading well-differentiated GEP-NETs, we generated and compared miRNA expression profiles from four pathological types of GEP-NETs. Using quantitative barcoded small RNA sequencing and state-of-the-art sequence annotation, we generated comprehensive miRNA expression profiles from archived pancreatic, ileal, appendiceal, and rectal NETs...
July 18, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/30009041/current-treatment-strategies-for-patients-with-advanced-gastroenteropancreatic-neuroendocrine-tumors-gep-nets
#5
REVIEW
Inbal Uri, Simona Grozinsky-Glasberg
Background: Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of ~ 6.9/100,000. NETs arise throughout the body from cells of the diffuse endocrine system. More than half originate from endocrine cells of the gastrointestinal tract and the pancreas, thus being referred to as gastroenteropancreatic NETs (GEP NETs). The only treatment that offers a cure is surgery, however most patients are diagnosed with metastatic disease, and curative surgery is usually not an option...
2018: Clinical Diabetes and Endocrinology
https://www.readbyqxmd.com/read/29987525/applying-reflective-multicriteria-decision-analysis-mcda-to-patient-clinician-shared-decision-making-on-the-management-of-gastroenteropancreatic-neuroendocrine-tumors-gep-net-in-the-spanish-context
#6
Monika Wagner, Dima Samaha, Jesus Cuervo, Harshila Patel, Marta Martinez, William M O'Neil, Paula Jimenez-Fonseca
INTRODUCTION: Unresectable, well-differentiated nonfunctioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can be monitored (watchful waiting, WW) or treated with systemic therapy such as somatostatin analogues (SSAs) to delay progression. We applied a reflective multicriteria decision analysis (MCDA) shared-decision framework (previously developed for the USA) to explore what matters to Spanish patients and clinicians considering GEP-NET treatment options. METHODS: The EVIDEM-derived framework was updated and adapted to the Spanish context...
July 9, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29950352/the-role-of-adding-somatostatin-analogues-to-peptide-receptor-radionuclide-therapy-as-a-combination-and-maintenance-therapy
#7
Anna Yordanova, Marcel M Wicharz, Karin Mayer, Peter Brossart, Maria A Gonzalez-Carmona, Christian P Strassburg, Rolf Fimmers, Markus Essler, Hojjat Ahmadzadehfar
PURPOSE: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy (PRRT) are validated therapies in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), it remains unclear whether SSA combined with PRRT or as maintenance therapy can provide prolonged survival compared to patients treated with PRRT alone. In this retrospective study, we aimed to investigate whether there is a survival benefit to adding SSA to PRRT as a combination therapy and/or maintenance therapy...
June 27, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29942397/peptide-receptor-radionuclide-therapy-and-the-treatment-of-gastroentero-pancreatic-neuroendocrine-tumors-current-findings-and-future-perspectives
#8
REVIEW
Nader Hirmas, Raya Jadaan, Akram Al-Ibraheem
Purpose and Methods: Patients with inoperable and metastasized neuroendocrine tumors (NETs), particularly those with grades 1 and 2, usually receive treatment with somatostatin analogues (SSAs). Peptide receptor radionuclide therapy (PRRT) has gained momentum over the past two decades in patients who progress on SSAs. 177Lu-DOTATATE is currently the most widely used radiopeptide for PRRT. We reviewed the recent evidence on PRRT and the treatment of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs)...
June 2018: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29934316/master-regulators-may-be-therapeutic-targets-for-precision-oncology
#9
(no author information available yet)
OncoTreat identified master regulators in gastroenteropancreatic neuroendocrine tumors (GEP-NET).
June 22, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29915428/a-precision-oncology-approach-to-the-pharmacological-targeting-of-mechanistic-dependencies-in-neuroendocrine-tumors
#10
Mariano J Alvarez, Prem S Subramaniam, Laura H Tang, Adina Grunn, Mahalaxmi Aburi, Gabrielle Rieckhof, Elena V Komissarova, Elizabeth A Hagan, Lisa Bodei, Paul A Clemons, Filemon S Dela Cruz, Deepti Dhall, Daniel Diolaiti, Douglas A Fraker, Afshin Ghavami, Daniel Kaemmerer, Charles Karan, Mark Kidd, Kyoung M Kim, Hee C Kim, Lakshmi P Kunju, Ülo Langel, Zhong Li, Jeeyun Lee, Hai Li, Virginia LiVolsi, Roswitha Pfragner, Allison R Rainey, Ronald B Realubit, Helen Remotti, Jakob Regberg, Robert Roses, Anil Rustgi, Antonia R Sepulveda, Stefano Serra, Chanjuan Shi, Xiaopu Yuan, Massimo Barberis, Roberto Bergamaschi, Arul M Chinnaiyan, Tony Detre, Shereen Ezzat, Andrea Frilling, Merten Hommann, Dirk Jaeger, Michelle K Kim, Beatrice S Knudsen, Andrew L Kung, Emer Leahy, David C Metz, Jeffrey W Milsom, Young S Park, Diane Reidy-Lagunes, Stuart Schreiber, Kay Washington, Bertram Wiedenmann, Irvin Modlin, Andrea Califano
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins that mechanistically regulate tumor cell state, as assessed from systematic drug perturbation assays. We validated the approach on a cohort of 212 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a rare malignancy originating in the pancreas and gastrointestinal tract...
June 18, 2018: Nature Genetics
https://www.readbyqxmd.com/read/29876704/ct-evaluation-of-response-in-advanced-gastroenteropancreatic-neuroendocrine-tumors-treated-with-long-acting-repeatable-octreotide-what-is-the-optimal-size-variation-threshold
#11
Yanji Luo, Jie Chen, Bingqi Shen, Meng Wang, Huasong Cai, Ling Xu, Luohai Chen, Minhu Chen, Zi-Ping Li, Shi-Ting Feng
OBJECTIVE: To identify a reliable early indicator of deriving progression-free survival (PFS) benefit in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with octreotide long-acting repeatable (LAR). METHODS: We investigated the images of 50 patients with well-differentiated advanced GEP-NETs treated with LAR octreotide and underwent baseline and follow-up thoracic, abdominal, and pelvic computed tomography. Receiver-operating characteristic (ROC) analysis and the Kaplan-Meier method were used to identify the optimal threshold to distinguish between those with and without significant improvement of PFS...
June 6, 2018: European Radiology
https://www.readbyqxmd.com/read/29873204/incidence-trend-and-conditional-survival-estimates-of-gastroenteropancreatic-neuroendocrine-tumors-a-large-population-based-study
#12
Qing Zhong, Qi-Yue Chen, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Jun Lu, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ze-Ning Huang, Ju-Li Lin, Ping Li, Chao-Hui Zheng, Chang-Ming Huang
Given the rarity and indolent clinical course of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), conditional survival might be the most suitable parameter for cancer survivors who wish to receive accurate prognostic information during follow-up. We have explored the updated incidence trend and the conditional survival of patients with GEP-NETs. Incidence trends from 2000 to 2014 were determined through an assessment of patients in the SEER cancer registry. Patients diagnosed between 1988 and 2011 were included in the conditional survival analysis, and the 3-year conditional cancer-specific survival (CCS3) was computed...
June 5, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29788534/prospective-evaluation-of-68-ga-dotatate-pet-ct-in-limited-disease-neuroendocrine-tumours-and-or-elevated-serum-neuroendocrine-biomarkers
#13
Sophie Gabriel, Philippe Garrigue, Laetitia Dahan, Frédéric Castinetti, Frédéric Sebag, Karine Baumstark, Cendrine Archange, Abhishek Jha, Karel Pacak, Benjamin Guillet, David Taïeb
CONTEXT: The 68 Ga-labelled somatostatin analogues (68 Ga-DOTA-SSAs) is becoming popular as an important diagnostic tool in neuroendocrine tumours as evidenced by a growing number of reports detailing institutional experience with various DOTA peptides. However, only few prospective studies have compared 68 Ga-DOTA-SSAs and somatostatin receptor scintigraphy (SRS) in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and pulmonary neuroendocrine tumours. OBJECTIVE: The aim of our prospective study was to perform head-to-head comparison between 68  Ga-DOTATATE PET/CT and standard imaging work-up (SI) that included multiphasic CT, liver MRI and SRS using single photon emission computed tomography...
May 22, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29781720/supplementation-of-vitamin-d-deficiency-in-patients-with-neuroendocrine-tumors-using-over-the-counter-vitamin-d3-preparations
#14
Helen L Robbins, Megan Symington, Barbara Mosterman, Josie Goodby, Louise Davies, Georgios K Dimitriadis, Gregory Kaltsas, Harpal S Randeva, Martin O Weickert
Vitamin D (vit-D) deficiency is highly prevalent in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) and has been linked to reduced overall survival. We here assessed the vit-D status in 183 patients with GEP-NET at the time of their first presentation in the ARDEN NET Centre. We further examined the effect of simple advice to increase vit-D intake using over-the-counter vit-D preparations [colecalciferol (Vit-D3), 1,000-2,000 units/day], over a prospective observation period of 24 mo...
July 2018: Nutrition and Cancer
https://www.readbyqxmd.com/read/29777005/predictors-of-survival-in-211-patients-with-stage-iv-pulmonary-and-gastroenteropancreatic-mibg-positive-neuroendocrine-tumors-treated-with-i-131-mibg
#15
Ari Kane, Matthew P Thorpe, Jorge D Oldan, Brandon A Howard, Jason Zhu, Michael A Morse, Terence Wong, Neil A Petry, Robert Reiman, Salvador Borges-Neto
Purpose: This retrospective analysis identifies predictors of survival in a cohort of patients with mIBG positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with I-131 mIBG therapy, in order to inform treatment selection and post-treatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from n = 211 P/GEP-NET patients treated with mIBG between 1991-2014. For patients with computed tomography (CT) follow up ( n = 125), imaging response was assessed by Response Evaluation Criteria on Solid Tumors (RECIST) 1...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29760558/pretreatment-hematologic-markers-as-prognostic-predictors-of-gastroenteropancreatic-neuroendocrine-tumors-a-systematic-review-and-meta-analysis
#16
Yu Zhou, Dezhi Li, Ye Lin, Min Yu, Xin Lu, Zhixiang Jian, Ning Na, Baohua Hou
Background: Systemic inflammation can be reflected by peripheral hematologic parameters and combined index like the lymphocyte count, neutrophil count, platelet count, neutrophil-to-lymphocyte (NLR), and platelet-to-lymphocyte ratio (PLR). This systematic review and meta-analysis aimed to summarize the association between the hematologic markers and prognosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: A computerized systematic search of PubMed, Embase, and Web of Science was conducted up to August 2016...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29744856/risk-factors-associated-with-gastroenteropancreatic-neuroendocrine-tumors-gep-net-in-a-cohort-of-2-3-million-israeli-adolescents
#17
L H Katz, Z Levi, G Twig, J D Kark, A Leiba, E Derazne, I Liphshiz, L K Boker, S Eisenstein, A Afek
We investigated whether obesity and socio-demographic factors at adolescence are associated with incident gastroenteropancreatic neuroendocrine tumors (GEP-NET).Our cohort included 2.3 million Israeli adolescents examined at ages 16 to 19 years between 1967 and 2010. The baseline database included sex, country of birth, residential socio-economic status (SES), body-mass index (BMI) and height. Participants were followed through linkage with the National Cancer Registry up to 2012. We identified 221 cases of GEP-NET (66 pancreatic, 52 gastric, 39 rectal, 27 appendiceal, 23 small bowel and 14 colonic)...
May 9, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29704389/recommended-parameters-for-pathology-reporting-of-gastroenteropancreatic-neuroendocrine-tumours-gep-nets
#18
(no author information available yet)
No abstract available.
April 2018: Malaysian Journal of Pathology
https://www.readbyqxmd.com/read/29685756/treatment-challenges-in-and-outside-a-network-setting-gastrointestinal-neuroendocrine-tumours
#19
REVIEW
Faidon-Marios Laskaratos, Martyn Caplin
Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are relatively rare neoplasms arising from the enterochromaffin cells of the gastrointestinal tract. They comprise a heterogeneous group of tumours with a diverse natural history, variable biological behaviour and different clinical outcomes. Their management is often complex and may include a combination of surgery, systemic treatments and locoregional approaches. A multidisciplinary team approach is therefore essential for the optimal care of patients with GEP NETs...
March 22, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29610193/fda-approves-lutathera-for-gep-net-therapy
#20
(no author information available yet)
No abstract text is available yet for this article.
April 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
163564
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"